Abstract
The role of race/ethnicity in genetic predisposition of early-onset cancers can be estimated by comparing family-based cancer concordance rates among ethnic groups. We used linked California health registries to evaluate the relative cancer risks for first degree relatives of patients diagnosed between ages 0-26, and the relative risks of developing distinct second malignancies (SPMs). From 1989-2015, we identified 29,631 cancer patients and 62,863 healthy family members. Given probands with cancer, there were increased relative risks of any cancer for siblings and mothers [standardized incidence ratio (SIR)=3.32;95% confidence interval (CI):2.54-4.35;P<0.001)]and of SPMs (SIR=7.12;95%CI:5.46-9.28;P<0.001). Higher relative risk of any cancer in siblings and mothers (P=0.001) was observed for Latinos (SIR=3.36;95%CI:2.24-5.05) compared to non-Latino White subjects (SIR=2.60;95%CI:1.66-4.06). Latinos had higher relative risks in first degree relatives and higher SPM risk compared to non-Latino Whites for most cancers, supporting a need for increased attention to the genetics of early-onset cancer predisposition in Latinos.
Key Messages
We identified 29 631 cancer patients and their 62 863 healthy family members in California from 1989 to 2015.
The risk of early-onset cancer in siblings and mothers was elevated by having a proband with cancer in the same family.
The majority of early-onset cancers exhibited higher relative risks in siblings and mothers and second primary malignancies for Latinos when compared to non-Latino Whites.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the V Foundation for funding this work (Grant FP067172).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the California Committee on Protection of Human Subjects, the IRB for the State of California (protocol 17-04-2958), with reviews also at IRBs at USC and UCSF.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We are prohibited by the State of California from sharing individual-level patient data.
